

April 16, 2021

Announcements

Dr. Amit Khanna Appointed Director of Colon and Rectal Surgery for Bridgeport Region

We are pleased to announce the appointment of Amit Khanna, MD, MPH, FACS, Associate Professor of Surgery (Colon and Rectal Surgery) and Director of Colon and Rectal Surgery for the Bridgeport region. Dr. Khanna will be responsible for leading colorectal surgical services in the Bridgeport and Trumbull area, in collaboration with the Digestive Health service line and Smilow Cancer Hospital Network teams.

Dr. Khanna joins Yale via Tower Health System where he was Chief of Colon and Rectal Surgery and Director of Digestive Health Services in Philadelphia. He brings more than 20 years of experience as a high-volume surgeon, specializing in the minimally invasive treatment and management of inflammatory bowel disease, colorectal malignancy, and anorectal diseases.

Dr. Khanna graduated from Mount Sinai/NYU School of Medicine and completed his general surgical training at the University of Rochester, Strong Memorial Hospital. He then pursued a fellowship in colon and rectal surgery at The Cleveland Clinic Florida. He has a master's in public health in Health Policy and Management from Columbia University School of Public Health.

Dr. Vikram Reddy Named Chief of Colon and Rectal Surgery

Vikram Reddy, MD, PhD, Associate Professor of Surgery, has been appointed as the new Chief of Colon and Rectal Surgery. Dr. Reddy succeeds Dr. Walter E. Longo, who led Gastrointestinal Surgery as

Division Chief since 2003. In his



from the desk of

Nita Ahuja, MD, MBA, FACS

Interim Director, Yale Cancer Center
Interim Physician-in-Chief,
Smilow Cancer Hospital

Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center

Immune-boosting drug may help before lung cancer surgery



Watch Now

Yale Cancer Center Study Provides New Insights into Resistance to Immune Checkpoint Inhibitors

new role, Dr. Reddy will be responsible for managing the clinical, research, and financial growth of Colon and Rectal Surgery. Dr. Longo will continue his tenure as a full-time faculty member and Professor, including his leadership activity in the Digestive Health Service Line.



Dr. Reddy completed his general surgical residency at Yale and, in 2009, returned to Yale as Dr. Longo's first faculty recruit to the GI program. Dr. Reddy quickly established a national reputation for his expertise in chronic inflammatory bowel disease and the laparoscopic management and screening of anorectal cancer. Dr. Reddy is pursuing a Master of Business Administration at Yale.

Radiation Oncology Chiefs

Dr. Peter Glazer, Chief of Therapeutic Radiology, has announced an updated list of service chiefs for radiation oncology throughout the Smilow Cancer Hospital Network. In their specific areas, the disease site chiefs will work with other departmental and Smilow leadership and staff to advance Smilow programs and ensure safe, state-of-the-art care.

Radiation Oncology Chiefs of Service are as follows:

- Breast Cancer: Dr. Meena Moran
- Cardiac Brachytherapy: Dr. Kenneth Roberts
- Central Nervous System: Dr. Joseph Contessa
- Gamma Knife: Dr. James Hansen
- Gastrointestinal Cancers: Dr. Kimberly Johung
- Genitourinary Cancers: Dr. Yi An
- Gynecologic Oncology: Dr. Shari Damast
- Head and Neck Cancers: Dr. Melissa Young
- Lymphoma/Sarcoma: Dr. Kenneth Roberts
- Pediatrics: Dr. Kenneth Roberts
- Pediatric CNS: Dr. Ranjit Bindra
- Spine: Dr. Yi An
- Thoracic: Dr. Henry Park
- VA: Dr. Kimberly Johung

Upcoming CME Programs

Yale Cancer Center and Smilow Cancer Hospital are sponsoring several upcoming CME programs. Please register to hear your colleagues present, and share these opportunities with community physicians and other contacts.


Today at Noon:

[**Evolving Surgical Strategies in Breast Cancer Register**](#)

May 4 at 6pm:


[**The Susan Beris, MD, Brain Tumor CME Seminar**](#)

in Lung Cancer




[Read More](#)

Yale Cancer Center Study Shows Young Early-Onset Colorectal Cancer Patients Have Increased Survival



[Read More](#)

Yale Cancer Center Study Shows Novel Immunotherapy Approach to Fight Melanoma



[Read More](#)

Head and Neck Cancer: Five Things You Need to Know



[Read More](#)

[Register](#)

May 27 at 12pm:

[Therapeutic Advances for Breast Cancer](#)

[Register](#)

Yale Breast Cancer Summit

Please register to join us for a Breast Cancer Research Summit on Thursday, May 6 from 8am-1pm via [Zoom](#). Topics will include Obesity, Metabolism, and Breast Cancer; Cancer Survivorship and Outcomes Research; DNA Damage and Breast Cancer; and Technology and Resources.

Notables

Nikolai Podoltsev, MD, PhD, Associate Professor of Medicine (Hematology) and a member of Yale Cancer Center's Developmental Therapeutics Research Program, and **Xiaomei Ma, PhD**, Professor of Epidemiology (Chronic Diseases) and Co-Leader of the Cancer Prevention and Control Research Program, have received a generous three-year award from **The Frederick A. DeLuca Foundation**. The grant will fund their research to examine the potential role of early-life environmental exposures, genetics, and metabolomics in the etiology of early-onset myeloproliferative neoplasms. Other collaborators include Caroline Johnson, PhD, Assistant Professor of Epidemiology (Environmental Health Sciences), Andrew DeWan, PhD, MPH, Associate Professor of Epidemiology (Chronic Diseases), and Rong Wang, PhD, Research Scientist in Epidemiology.


Jun Lu, PhD, Professor of Therapeutic Radiology and a member of Yale Cancer Center's Genomics, Genetics, and Epigenetics Research Program, has received a multi-institutional collaborative research grant by the **Department of Energy** to study "Dynamic Multiscale Digital Twin for a Lung Cancer Patient." Dr. Lu is Co-Principal Investigator on the grant along with Qi Wang, PhD, at the University of South Carolina.

Michaela Dinan, PhD, Associate Professor of Epidemiology (Chronic Diseases) and Co-Leader of Yale Cancer Center's Cancer Prevention and Control Research Program, has been awarded a Research Scholar Grant from the **American Cancer Society** to fund her research project, "Development of Cancer Survivorship Risk Models to Inform Pathways of Care."

En Cheng, MD, MSPH, received a **AACR-AbbVie Scholar in Training Award** in recognition of his abstract at AACR, "Survival for patients with early-onset colorectal cancer – An overall survival analysis from the National Cancer Database, 2004-2015."



Join Smilow Cancer Hospital on Facebook



The YWBC SLEEP study explores potential stressors and their impact on sleep in young breast cancer survivors after treatment. The goal of the study is to understand sleep experiences and what contributes to sleep in young women with breast cancer. Women who were diagnosed with stage 1 – 3 breast cancer at age of 50 or younger may qualify.

How is your sleep?

Sleep disturbance is one of the most common side effects in breast cancer survivors, but we don't know what the sleep experience is like among ***young women with breast cancer.***

Share your sleep experiences and join our study.



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated by the National Cancer Institute

Read More

Trained in cancer molecular biology, Yale Cancer Center member Darryl Martin, PhD, is tackling genitourinary cancers with a bench-to-bedside team intent on finding better treatments.



This year's **Oncology Nursing Society Congress** will have incredible representation from our oncology nursing team from Smilow Cancer Hospital and Yale Cancer Center thanks to the dedicated efforts of our nurses and many mentors throughout our health system. The following abstracts have been accepted for presentation at this year's Congress. Please login to support your colleagues if you are attending or review the content in the On-Demand Library through May 27.

Daily COVID-19 Call Monitoring in Oncology Patients
Brianna Lutz, Kylie Kuck

Codes Over Coffee: Improving Resiliency in Oncology Nursing
Marcelle Gosteli, Brianna Lutz

Establishing a COVID-19 Minimal Pathway in Oncologic Surgery
Rebecca Halpern, Cara Henderson, Tracy Carafeno, Daniel Boffa

Utilizing Flipped Classroom Strategies to Maintain Student Satisfaction in a Hybrid Teaching Model
Cathy Sumpio, Evanica Rosselli

Supporting the General Surgery Nurse in the Post-operative Care of the Oncologic Patient
Cara Henderson, Rebecca Halpern, Tracy Carafeno, Hayley Cummings, Gail Lebrun, Brittney Watts

Rapid Relocation of 13 Hospital Based Ambulatory Care Teams to Satellite Centers: Two Oncology Nurse Leaders' VUCA (Volatile, Uncertain, Complex and Ambiguous) Leadership Skills During Covid-19 Pandemic
Kathleen Moseman, Camille Servodidio

Measurement of Orthostatic Vital Signs Reduces Falls in the Hematopoietic Stem Cell Transplant Population of a Hematology Oncology Unit
Jill Williams, Kirsten Pedersen, Tanaz Mistry

Huddle For Safety: Interdisciplinary Communication at a Critical Point in the Care Continuum
Elisa Riccitelli, Camille Servodidio, Bethany Larkin, Kristy Garuti

Engaging Staff in Hospital Based Award and Recognition Nominations
Camille Servodidio, Sandra Hurd, Bethany Larkin

Creating a Cellular Therapy Simulation Course
Kirsten Pedersen, Kylie Kuck

Chemotherapy Telehealth Patient Education Visit
Nicole Bocchetta, Catherine Sumpio, Kirsten Pedersen

Ensuring Chemotherapy Competency during the COVID-19 Pandemic
Evanica Rosselli, Kirsten Pedersen, Christina Matousek, Patricia Szabo, Ryan Telford, Elizabeth Gineo

Establishing and Sustaining a Multidisciplinary Cancer COVID-19



[Read More](#)

The partnership of Craig Crews, PhD, and Daniel Petrylak, MD, has brought ARV-110, a proteolysis-targeting chimaera, or PROTAC, to clinical trials at Smilow Cancer Hospital for men with metastatic castration-resistant prostate cancer. PROTACs work by using elements of the body's natural protein recycling system, and recruiting them towards cancerous proteins.



[Read More](#)

Learn how Yale scientists joined forces to unlock the secrets of DNA repair and its impact on cancer thanks to a gift from the Gray Foundation.



[Read More](#)

In recognition of Head and Neck Cancers Awareness Month, Dr. Aarti Bhatia joined us on Yale Cancer Awareness to discuss the latest treatment

Kim Slusser

APP Challenges During COVID-19: How We Weathered The Pandemic

Vanna Dest

Oncology Ambulatory Blood Transfusion: Getting Blood in your Backyard!

Mandeep Smith, Paula Pike, Krista Bello, Monica Fradkin

A Model for the Provision of Urgent Care to Oncology Patients during a Global Pandemic

Lisa Barbarotta, Tracy Carafeno, Vanna Dest, Brianna Lutz, Kylie Kuck, Kim Slusser


The Association of American Physicians (AAP) has elected two Yale Cancer Center members to its membership for 2021: **Gary V. Desir, MD**, Chair of Internal Medicine, Paul B. Beeson Professor of Medicine, and Vice Provost for Faculty Development and Diversity; **David A. Hafler, MD**, Chair and William S. and Lois Stiles Edgerly Professor of Neurology, and Professor of Immunobiology. AAP's goals include the pursuit of medical knowledge and the advancement through experimentation and discovery of basic and clinical science and their application to clinical medicine.

The **American Society for Clinical Investigation (ASCI)** has elected **Joseph N. Contessa, MD, PhD**, Professor of Therapeutic Radiology and of Pharmacology, Vice chair for Basic Science Research in Therapeutic Radiology, and Co-Leader of Yale Cancer Center's Radiobiology and Radiotherapy Research Program and **Peggy Myung, MD, PhD**, Assistant Professor of Dermatology and Pathology to its membership. The ASCI is dedicated to the advancement of research that extends our understanding and improves the treatment of diseases of all people, and members are committed to mentoring future generations of physician-scientists of diverse backgrounds and biomedical disciplines.

Grace Kong, PhD, Assistant Professor of Psychiatry and a member of Yale Cancer Center's Cancer Prevention and Control Research Program, has been appointed to the **National Academies of Sciences, Engineering, and Medicine's (NAEM)** Committee on Health Effects and Patterns of Use of Premium Cigars.

Fifth-year Yale School of Medicine (YSM) MD-PhD student **Ryan Dz-Wei Chow** is one of 30 graduate students selected for the **Paul & Daisy Soros Fellowships for New Americans**. Ryan works in the Yale Cancer Center lab of **Sidi Chen, PhD**, who describes him as "an outstanding student, excellent scientist, and awesome human being. He's absolutely the future star!"

Cancer Answers to discuss the latest treatment options and clinical trials. Listen online to hear her interview, or download our podcast from iTunes.



[Read More](#)

The Department of Therapeutic Radiology is pleased to announce the appointment of Allison Campbell, MD, PhD, to Assistant Clinical Professor of Therapeutic Radiology. Dr. Campbell will join the Smilow Cancer Hospital Care Center in Greenwich this month. She recently completed a fellowship in SRS/SBRT as a Radiosurgery Fellow in the Departments of Therapeutic Radiology and Neurosurgery at Yale, where she also completed her residency in Therapeutic Radiology and served as Chief Resident. Dr. Campbell received her medical degree and her PhD in Immunobiology from Yale School of Medicine. In 2015, Dr. Campbell received the MD/PhD Award from Yale, which is awarded to an outstanding member of the graduating class who has shown excellence in both research and clinical activities.



Allison Campbell, MD, PhD, appointed Assistant Clinical Professor of Therapeutic Radiology and will join Smilow Cancer Hospital Care Center in Greenwich

[Read More](#)

We are pleased to announce Dr. Bohdan Pomahac as Division Chief of Plastic & Reconstructive Surgery, effective July 1, 2021. Dr. Pomahac joins the Yale Surgery and Smilow Cancer Hospital community from Brigham and Women's Hospital and

The Cancer Signaling Networks (CSN) Research Program welcomes **Matthew Rodeheffer, PhD, Associate Professor of Medicine** (Comparative Medicine). Dr. Rodeheffer's research provides insights into mechanisms by which dietary factors and obesity predispose to cancer, including crosstalk of tumor cells, adipocytes, and obesity-dependent systemic metabolic changes. He is currently collaborating with CSN members on a project to investigate impact of specific fatty acids on breast cancer and pancreatic cancer.



Employee Profile: Vanna Dest

Vanna Dest, MSN, APRN, BC, AOCN, has been in oncology nursing since 1984 when she started as a staff nurse at the Hospital of Saint Raphael. She received her master's from Yale School of Nursing in 1992 and practiced as an oncology clinical nurse specialist in radiation at Saint Raphael's and later pursued her Post-Master's Certificate in Oncology at Yale School of Nursing in 2002. She is currently the Senior Program Manager of the Oncology Advanced Practice Providers (APP) at Smilow Cancer Hospital and an Oncology Nurse Practitioner as part of the Center for Thoracic Cancers. She is a Clinical Lecturer at the Yale School of Nursing and has been teaching in the Oncology APRN Program/Concentration since 2008.



Vanna provides day to day administrative oversight and support for all oncology APPs. She fosters communication and their professional development. She is also involved in direct patient care for patients with thoracic malignancies. As part of the Extended Care Clinic, which

community from Brigham and Women's Hospital and Harvard Medical School, where he is the Roberta and Stephen R. Weiner Distinguished Chair in Surgery and Director of Vascular Composite Allograft Transplantation program.

A pioneer in his field, Dr. Pomahac's team performed the first three full-face transplant procedures in the United States, and the first successful bilateral upper extremity transplantation in the Northeast. Dr. Pomahac made Brigham and Women's Hospital the world leader in vascularized composite transplantation completing 10 face and 3 bilateral hand transplants.

Dr. Pomahac's expertise will add to a growing portfolio of destination programs in the Division of Plastic & Reconstructive Surgery at Yale, which, since Dr. John Persing's appointment as Chief in 1992, has grown into a multidisciplinary enterprise—with novel programs across Connecticut, including wound healing, craniofacial surgery, melanoma treatment, targeted muscle reinnervation, breast reconstruction, and cutting-edge research in machine learning and 3D printing. Dr. Persing announced his retirement at the end of June and we are grateful for his leadership and dedication over his 29-year career at Yale.

A blue graphic with white text. At the top, it says "Welcome to Smilow Cancer Hospital". Below that is a photo of Bohdan Pomahac, MD, a man with glasses and a beard, wearing a white lab coat. To the right of the photo, it says "Bohdan Pomahac, MD, Appointed Chief of Plastic & Reconstructive Surgery". At the bottom left, it says "YaleNewHavenHealth Smilow Cancer Hospital". At the bottom right, it says "Yale CANCER CENTER A Comprehensive Cancer Center Designated by the National Cancer Institute".

[Read More](#)

Follow Yale Cancer Center on Twitter

Follow us on [twitter](#)

 At the heart of [@SmilowCancer](#) and [@YaleCancer](#), our commitment to safety, compassionate care, and research excellence will always remain

with thoracic malignancies. As part of the Extended Care Clinic, which opened in 2018, Vanna delivers urgent care to patients and provides opportunities for patients who need supportive care outside of normal clinic hours. Since the Smilow Rapid Evaluation Clinic opened last April, Vanna has worked to provide quick evaluation and testing of Smilow patients for symptoms of COVID-19, facilitating triage to the most appropriate location of care.

Vanna commented, "Oncology nursing has been my passion since my early teenage years and I truly could not imagine doing anything else. Although COVID has complicated things, our oncology patients continue to show tremendous strength and courage. In my current role, I feel that I have the best of both worlds—caring for patients and supporting and developing our dedicated, highly gifted APP team at Smilow Cancer Hospital and the Care Centers."

Recent Publications

Chae, W. J., & Bothwell, A.

Dickkopf1: An immunomodulatory ligand and Wnt antagonist in pathological inflammation.

Differentiation; research in biological diversity, 108, 33–39.

[Read More](#)

Rodrigues Pessoa R, Mueller AC, Boxley P, Flaig TW, Piper C, Konety B, Yu JB, Gershman B, Kukreja J, Kim SP.

Systematic Review and Meta-analysis of Radiation Therapy for High-risk Non-muscle Invasive Bladder Cancer.

Urologic Oncology, Online ahead of print.

[Read More](#)

Torabi SJ, Kastle DA, Su-Velez BM, Mehra S, Day TA, Yarbrough WG, St John M, Judson BL.

A 2020 Update on Public Awareness of Head and Neck Cancers.

Otolaryngology-Head & Neck Surgery, Online ahead of print.

[Read More](#)

Samarasinghe KTG, Jaime-Figueroa S, Burgess M, Nalawansha DA, Dai K, Hu Z, Bebenek A, Holley SA, Crews CM.

Targeted Degradation Of Transcription Factors By TRAFACs: TRANscription Factor TArgeting Chimeras.

Cell Chemical Biology, Online ahead of print.

[Read More](#)

Mitchell SM, Graham M, Liu X, Leonhardt RM.

Identification of Critical Amino Acid Residues in the Regulatory N-terminal Domain of PMEL.

Scientific Reports.

[Read More](#)

Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross JS, Syrigos K, Wei W, Pusztai L, Rimm DL, Vathiotis IA.

Comparison of Programmed Death-Ligand 1 Protein Expression

expression will always remain.



The partnership of @CraigMCrews and @DanielPetrylak has brought ARV-110, a proteolysis-targeting chimaera, or PROTAC, to clinical trials @SmilowCancer for men with metastatic castration-resistant #prostatecancer.



Log in to #AACR21 at 1:30pm today to hear @DrRoyHerbstYale moderate a panel discussion on #Tobacco Control with KrishnanSarin and colleagues from the @AACR Tobacco Products and Cancer Subcommittee.



Log in to #AACR21! Study results from Dr. Donald Engelman show "MicroRNA function is malleable and can be governed by target gene expression levels."



In a poster presentation at #AACR21, Dr. Alessandro Santin led a study showing in vitro and in vivo activity of an antibody-drug conjugate targeting HER2/neu in #endometrialcancer.



New research led by Dr. Scott Gettinger at #AACR21 reports on a phase 2, multicenter study of autologous tumor infiltrating lymphocytes in patients with solid tumors.



Learn how @YaleCancer scientists joined forces to unlock the secrets of #DNArepair and its impact on cancer thanks to a gift from the Gray Foundation.



Join .@MehraGolshan @GreenupRachel @eberger32 and Melanie Lynch for a #CME program sharing the latest surgical strategies and innovations for #breastcancer on Friday, April 16 at noon via Zoom.



Congratulations to Camila Robles-Oteiza, PhD student @politikaterina lab, awarded a Women in Cancer Research Scholar at this year's #AACR21. She's a scientist-in-training and presenter of a meritorious scientific paper.



New research led by Dr. Patricia LoRusso at #AACR21 reports on a "First-in-human phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors."



Log in to virtual #AACR21 to read new research led by @SanjayAnejaMD reporting on the "Utility of deep metric learning for

Comparison of Programmed Death-1 and PD-1 Protein Expression between Primary and Metastatic Lesions in Patients with Lung Cancer.

Journal for Immunotherapy of Cancer.

[Read More](#)

Janku F, LoRusso P, Mansfield AS, Nanda R, Spira A, Wang T, Melhem-Bertrandt A, Sugg J, Ball HA.

First-in-human Evaluation of the Novel Mitochondrial Complex I Inhibitor ASP4132 for Treatment of Cancer.

Investigational New Drugs, Online ahead of print.

[Read More](#)

LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM.

Identifying Treatment Options for BRAFV600 Wild-type Metastatic Melanoma: A SU2C/MRA Genomics-enabled Clinical Trial.

PLOS One.

[Read More](#)

Li F, Tong G.

Sample Size Estimation for Modified Poisson Analysis of Cluster Randomized Trials with a Binary Outcome.

Statistical Methods in Medical Research, Online ahead of print.

[Read More](#)

King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL.

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.

American Journal of Clinical Dermatology, Online ahead of print.

[Read More](#)

Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA.

Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.

Advances in Therapy, Online ahead of print.

[Read More](#)

Jain D, Torres R, Celli R, Koelmel J, Charkoftaki G, Vasiliou V.

Evolution of the Liver Biopsy and its Future.

Translational Gastroenterology and Hepatology.

[Read More](#)

Lu SX, Huang YH, Liu LL, Zhang CZ, Yang X, Yang YZ, Shao CK, Li JM, Xie D, Zhang X, Jain D, Yun JP.

α -Fetoprotein mRNA in situ Hybridisation is a Highly Specific Marker of Hepatocellular Carcinoma: A Multi-Centre Study

on the utility of deep metric learning for #breastcancer identification on mammographic images."



A poster presentation at #AACR21 led by @AlexanderTong7 @KrishnaswamyLab

shares understanding progression in triple negative #breastcancer using a novel computational method called TrajectoryNET.



Log in to #AACR21 for a poster presentation led by Dr. Camila Robles-Oteiza showing new insights into resistance to immune checkpoint inhibitors in #lungcancer.

Calendar

Yale Breast Cancer CME Series

April 16; 12:00 PM

Evolving Surgical Strategies in Breast Cancer

Elizabeth Berger, MD, MS | Melanie Lynch, MD | Rachel Greenup, MD, MPH

[Learn More](#)

Yale Cancer Center Chalk Talk

April 16; 4:30 PM

Investigating the Role of Stem-Like Cancer Cells in Malignant Brain Tumors

Sheila Alcantara Llaguno, MD, PhD

[Learn More](#)

Yale Cancer Answers

April 18; 7:30 PM

NPR

Cancer Care in the Community

Anamika Katoch, MD

[Learn More](#)

Yale Pancreatic Cancer Collaborative Seminar Series

April 19; 2:00 PM

The Seven Deadly Hallmarks of Pancreatic Cancer

David Tuveson, MD, PhD

[Learn More](#)

Yale Cancer Center Grand Rounds

April 20; 12:00 PM

Exocyst Mediated Recycling of Primary

Cilia and High Throughput Tools to Dissect SARS-CoV-2 Replication

Derek Toomre, PhD and Brett Lindenbach, PhD

[Learn More](#)

Recovery Seminar

Marker of Hepatocellular Carcinoma: A Multi-Centre Study.

British Journal of Cancer, Online ahead of print.

[Read More](#)

Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP.

Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old.

Journal of the National Cancer Institute, Online ahead of print.

[Read More](#)

Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M.

Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).

Annals of Surgical Oncology, Online ahead of print.

[Read More](#)

Kibbi N, Wang D, Wang WL, Galan A, Leffell DJ, Christensen SR, Panse G.

Dermatofibrosarcoma Protuberans in Pregnancy: A Case Series and Review of the Literature.

International Journal of Dermatology, Online ahead of print.

[Read More](#)

Ko CJ, Wang A, Panse G, Lee EE, Wang RC, Whang PG, Bosenberg M, Damsky W.

HPyV6- and HPyV7-negative Parakeratosis and Dyskeratosis in Squamous Cell Carcinoma in situ.

Journal of Cutaneous Pathology, Online ahead of print.

[Read More](#)

Birenbaum-Carmeli D, Inhorn MC, Vale MD, Patrizio P.

Cryopreserving Jewish Motherhood: Egg Freezing in Israel and the United States.

Medical Anthropology Quarterly, Online ahead of print.

[Read More](#)

Saffo S, Peng C, Salem R, Taddei T, Nagar A.

Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma.

Digestive Diseases and Sciences, Online ahead of print.

[Read More](#)

Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney DM, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, Unger JM, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, Hershman DL, Ramsey SD.

Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN).

JCO Oncology Practice, Online ahead of print.

[Read More](#)

Bereavement Seminar

April 20; 5:30 PM

Understanding and Managing Grief: How Long Am I Going to Feel Like This?

[Learn More](#)

Smilow Shares, Presented by the Smilow Cancer Hospital Care Center in Greenwich

April 20; 7:00 PM

Head & Neck Cancers: Understanding the Latest Treatment Advances

Barbara Burtness, MD | Benjamin Judson, MD | Bruce McGibbon, MD

[Learn More](#)

Medical Library Associates Lecture 2021

April 21; 4:00 PM

Epigenetic Health: Rethinking Aging and Cancer

Nita Ahuja, MD, MBA, FACS

[Learn More](#)

Yale Head & Neck SPORE Monthly Meeting

April 21; 6:00 PM

[Learn More](#)

Therapeutic Radiology Grand Rounds

April 22; 9:00 AM

Imaging Radiation Delivery in Real Time: Cherenkov Light Emission from Patients

Brian W. Pogue, PhD

[Learn More](#)

Palliative Care and Symptom Science (PASS) Seminar

April 22; 12:00 PM

Jaclyn Portanova, PhD, RN

[Learn More](#)

Pathology Grand Rounds

April 22; 12:30 PM

At the Crossroads of Epigenetics and Angiogenesis: Targeting the Undruggable

James Brugarolas, MD, PhD

[Learn More](#)

Cancer Genetics and Prevention Seminar

April 22; 2:30 PM

[Learn More](#)

Center for GI Cancers Weekly Seminar

April 22; 4:15 PM

Mandar Deepak Muzumdar, MD

[Learn More](#)

Yale Cancer Answers

April 25; 7:30 PM

de Bono JS, Fleming MT, Wang JS, Cathomas R, Selvi Miralles M, Bothos J, Hinrichs MJ, Zhang Q, He P, Williams M, Rosenbaum AI, Liang M, Vashisht K, Cho S, Martinez P, Petrylak DP.

Phase I Trial of MEDI3726, A Prostate-specific Membrane Antigen-targeted Antibody-drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.

Clinical Cancer Research, Online ahead of print.

[Read More](#)

Bade BC, Gan G, Li F, Lu L, Tanoue L, Silvestri GA, Irwin ML.

Randomized Trial of Physical Activity on Quality of Life and Lung Cancer Biomarkers in Patients with Advanced Stage Lung Cancer: A Pilot Study.

BMC Cancer.

[Read More](#)

Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA.

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.

JAMA Oncology, Online ahead of print

[Read More](#)

Funding and Award Opportunities

Cancer Grand Challenges Program

The NCI and Cancer Research UK (CRUK) are partnering to fund the Cancer Grand Challenges program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer. These nine challenges are aimed at solving complex problems in cancer research, which, if solved, could have a transformative impact towards progress.

Application Deadline: April 22, 2021

[Read More](#)

Yale SPORE in Lung Cancer

- **Career Enhancement Award:** The goal of the CEP of the YSILC is to educate the next generation of investigators committed to translational research in lung cancer. The CEP will provide support of up to \$50,000 to promising junior investigators and/or established investigators who have not previously conducted lung cancer focused research.
- **Developmental Research Program:** To provide seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated into, a full YSILC project.

Letters of Intent Due: April 23, 2021

[Read More](#)

Alex's Lemonade Stand - Crazy 8 Initiative

April 25, 7:30 PM

NPR

Understanding Medical Research

F. Perry Wilson, MD, MSCE

[Learn More](#)

Radiobiology and Radiotherapy Research Program

April 26; 11:00 AM

Understanding Altered RNA Splicing in Pancreatic Cancer Development and Therapy Resistance
Cancer Patients

Natasha Pinto Medici

[Learn More](#)

Visiting Speaker Series

April 26; 12:00 PM

Estrogen Receptor Function Domains: Physiological and Clinical Evaluation

Kenneth S. Korach, PhD

[Learn More](#)

YCC Genetics, Genomics and Epigenetics Research Seminar

April 26; 1:00 PM

Targeting Genetic and Host Drivers of Pancreatic Ductal Adenocarcinoma

Mandar Deepak Muzumdar, MD

[Learn More](#)

Molecular Biophysics & Biochemistry Seminar

April 26; 4:00 PM

Protein Dynamics: Connecting In Vitro, In Cell, And In Vivo

Caitlin Davis, PhD

[Learn More](#)

Yale Cancer Center Grand Rounds

April 27; 12:00 PM

Promoting Resilience in Children with Serious Illness and their Families

Abby R. Rosenberg, MD, MS, MA

[Learn More](#)

Bereavement Workshop

April 27; 5:30 PM

Adults Grieving the Death of a Parent

[Read More](#)

Center for Methods in Implementation and Prevention Science (CMIPS) Yale Center for Implementation Science (YCIS) Grand Rounds Series

April 28; 12:00 PM

Brian S. Mittman, PhD

[Read More](#)

Alex's Lemonade Stand - Crazy 8 Initiative

This initiative aims to tackle specific challenges in pediatric cancer research that require substantial support for collaborative teams. The Crazy 8 Initiative will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today.

Letter of Intent Due: April 26, 2021

[Read More](#)

NCCN/AstraZeneca Initiative Request for Proposals (RFP) in Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC)

The intent of this RFP is to encourage NCCN Member Institutions to submit LOIs describing concepts and ideas for developing, implementing, and evaluating healthcare provider performance and/or healthcare quality improvement initiatives to improve patient care and outcomes in early-stage NSCLC.

Letter of Intent Deadline: May 3, 2021

[Read More](#)

Pfizer Global Medical Grants - NSCLC Therapy Management for Optimal Outcomes

Projects that will be considered for Pfizer support will focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged NSCLC.

Application Deadline: May 5, 2021

[Read More](#)

NCCN/Pfizer/Astellas Request for Proposals (RFP): Enzalutamide in the Treatment of Prostate Cancer

The overall aim of this RFP is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer.

Letter of Intent Due: May 14, 2021

[Read More](#)

YHN SPORE Developmental Research Program

The Yale Head and Neck SPORE's Developmental Research Program (YHN-SPORE DRP) provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full YHN-SPORE project or to generate preliminary data or evidence of collaboration for other new NIH grant applications.

Application Deadline: May 15, 2021

[Read More](#)

YHN SPORE Career Enhancement Program

The Career Enhancement Program (CEP) of the Yale SPORE in Head and Neck Cancer (YHN-SPORE) has been established to educate the next generation of investigators committed to translational research in head and neck cancer. The CEP will provide support to promising junior investigators and/or establish investigators who have not previously conducted head and neck cancer focused research.

Application Deadline: May 15, 2021

[Read More](#)

[Read More](#)

Therapeutic Radiology Grand Rounds

April 29; 9:00 AM

Radiotherapy for Lower Gastrointestinal Malignancy: Recent Updates and Future Directions

Krishnan Jethwa, MD

[Read More](#)

Pathology Grand Rounds

April 29; 12:30 PM

Synthetic Lethal Therapy of HPB-Negative Head and Neck Cancer

Barbara Burtness, MD

[Read More](#)

Cancer Genetics and Prevention Seminar

April 29; 2:30 PM

[Read More](#)

Center for GI Cancers Weekly Seminar

April 29; 4:15 PM

Pharma Pipeline Discussion: Natera

Angel A. Rodriguez, MD

[Read More](#)

Yale Cancer Center Seminar

April 29; 5:00 PM

Understanding The Determinants Of Effective Anti-Tumor Immunity In Renal Cell Carcinoma

David A. Braun, MD, PhD

[Read More](#)

Submissions

Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications

Breast Cancer Alliance Young Investigator Grant

To encourage a commitment to breast cancer research, the BCA invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers to apply for funding for the Young Investigator Grant.

Internal LOI Deadline: June 1, 2021

Read More

The Cure Starts Now Foundation Research Grants

Research questions considered - Disease Impact: Does the study propose an intervention or clinical tool that will reduce the morbidity or mortality from or potentially find a cure for pediatric brain cancer?

Innovation: Does the research study propose a novel approach or represent advancement in current treatment of pediatric brain cancer?

Application Deadline: June 1, 2021

Read More

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)

This FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries.

Application Deadline: June 2, 2021

Read More

Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program

The BMSF DCTCDP is a 2-year program designed to support the career development of early-stage investigator (as defined by NIH) physicians underrepresented in medicine, or physicians who have a demonstrated commitment to increasing diversity in clinical research, to become independent clinical trial investigators who are engaged in advancing health equity through their research and mentoring.

Application Deadline: July 2, 2021

Read More

Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

Application Deadline: June 4, 2021

Read More

The NCI Transition Career Development Award

- **K22 - Independent Clinical Trial Required-** This FOA represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. **Application Deadline:** June 12, 2021 **Read More**

- **K22 - Independent Clinical Trial Not Allowed-** This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical

trial. **Application Deadline:** June 12, 2021 **Read More**

- **K22 Independent Basic Experimental Studies with Humans Required-** This FOA is designed specifically for basic science experimental studies involving humans. **Application Deadline:** June 12, 2021 **Read More**

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)

This FOA is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.

Application Deadline: June 15, 2021

Read More

NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC)

These FOAs support the NCI CPTAC managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community.

- Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24): **Application Deadline:** June 30, 2021 **Read More**
- Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24): **Application Deadline:** June 30, 2021 **Read More**
- Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01): **Application Deadline:** July 30, 2021 **Read More**

2021 ALSF 'A' Award Grant

The 'A' Award is a four-year grant designed for independent, early career scientists who demonstrate a commitment to pediatric cancer research and have institutional support for their career development.

Application Deadline: June 18, 2021

Read More

Tobacco Regulatory Science (R01)

The purpose of this FOA is to invite R01 applications to support

biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Application Deadline: July 14, 2021

Read More

Centers on Telehealth Research for Cancer-Related Care (P50)

The purpose of this FOA is to fund P50 Centers dedicated to advancing a national telehealth research agenda focused on improving cancer-related care and outcomes across the cancer control continuum in a rapidly changing healthcare, policy, technology, and communication environment.

Application Deadline: July 20, 2021

